Inhalable nanoparticles delivery targeting alveolar macrophages for the treatment of pulmonary tuberculosis
Pulmonary tuberculosis is a highly prevalent respiratory disease that affects approximately a quarter of the world's population. The drug treatment protocol for tuberculosis is complex because the Mycobacterium tuberculosis (M. tuberculosis) invades macrophages and begins to infect. Thus treatm...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Chae, Jayoung [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2021transfer abstract |
|---|
| Schlagwörter: |
|---|
| Umfang: |
9 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Oral Squamous Cell Carcinoma in Three Related Kowari (Dasyuroides byrnei) - Saunders, Richard ELSEVIER, 2017, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:132 ; year:2021 ; number:6 ; pages:543-551 ; extent:9 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.jbiosc.2021.08.009 |
|---|
| Katalog-ID: |
ELV055854761 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV055854761 | ||
| 003 | DE-627 | ||
| 005 | 20230626042246.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220105s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jbiosc.2021.08.009 |2 doi | |
| 028 | 5 | 2 | |a /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001581.pica |
| 035 | |a (DE-627)ELV055854761 | ||
| 035 | |a (ELSEVIER)S1389-1723(21)00212-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 082 | 0 | 4 | |a 540 |a 660 |q VZ |
| 084 | |a 58.34 |2 bkl | ||
| 100 | 1 | |a Chae, Jayoung |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Inhalable nanoparticles delivery targeting alveolar macrophages for the treatment of pulmonary tuberculosis |
| 264 | 1 | |c 2021transfer abstract | |
| 300 | |a 9 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Pulmonary tuberculosis is a highly prevalent respiratory disease that affects approximately a quarter of the world's population. The drug treatment protocol for tuberculosis is complex because the Mycobacterium tuberculosis (M. tuberculosis) invades macrophages and begins to infect. Thus treatment usually includes combination therapy with several drugs such as rifampicin, pyrazinamide, isoniazid, and ethambutol over a long dosing period. Therefore, drug-delivery technologies have been developed to improve patient compliance with medication, reduce adverse effects, and increase effectiveness of the treatment. In the present review, we have discussed recent inhalable nanopharmaceutical systems for the treatment of pulmonary tuberculosis and investigated their design and effectiveness. We examined the underlying processes and characteristics of spray-drying technology and studied the formulation of a dry carrier using spray-drying method. Moreover, we reviewed various research articles on pulmonary delivery of nanoparticles using these carriers, and studied their alveolar macrophage targeting ability and therapeutic effects. Further, we appraised the effectiveness of nanoparticle inhalation therapy for the treatment of pulmonary tuberculosis and its potential as a treatment strategy for lung diseases. | ||
| 520 | |a Pulmonary tuberculosis is a highly prevalent respiratory disease that affects approximately a quarter of the world's population. The drug treatment protocol for tuberculosis is complex because the Mycobacterium tuberculosis (M. tuberculosis) invades macrophages and begins to infect. Thus treatment usually includes combination therapy with several drugs such as rifampicin, pyrazinamide, isoniazid, and ethambutol over a long dosing period. Therefore, drug-delivery technologies have been developed to improve patient compliance with medication, reduce adverse effects, and increase effectiveness of the treatment. In the present review, we have discussed recent inhalable nanopharmaceutical systems for the treatment of pulmonary tuberculosis and investigated their design and effectiveness. We examined the underlying processes and characteristics of spray-drying technology and studied the formulation of a dry carrier using spray-drying method. Moreover, we reviewed various research articles on pulmonary delivery of nanoparticles using these carriers, and studied their alveolar macrophage targeting ability and therapeutic effects. Further, we appraised the effectiveness of nanoparticle inhalation therapy for the treatment of pulmonary tuberculosis and its potential as a treatment strategy for lung diseases. | ||
| 650 | 7 | |a Spray-drying |2 Elsevier | |
| 650 | 7 | |a Pulmonary tuberculosis |2 Elsevier | |
| 650 | 7 | |a Alveolar macrophage targeting |2 Elsevier | |
| 650 | 7 | |a Drug delivery |2 Elsevier | |
| 700 | 1 | |a Choi, Yonghyun |4 oth | |
| 700 | 1 | |a Tanaka, Masayoshi |4 oth | |
| 700 | 1 | |a Choi, Jonghoon |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Saunders, Richard ELSEVIER |t Oral Squamous Cell Carcinoma in Three Related Kowari (Dasyuroides byrnei) |d 2017 |g Amsterdam [u.a.] |w (DE-627)ELV020602480 |
| 773 | 1 | 8 | |g volume:132 |g year:2021 |g number:6 |g pages:543-551 |g extent:9 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.jbiosc.2021.08.009 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 58.34 |j Lebensmitteltechnologie |q VZ |
| 951 | |a AR | ||
| 952 | |d 132 |j 2021 |e 6 |h 543-551 |g 9 | ||
| author_variant |
j c jc |
|---|---|
| matchkey_str |
chaejayoungchoiyonghyuntanakamasayoshich:2021----:naalnnprilseieyagtnavoamcohgsoteramn |
| hierarchy_sort_str |
2021transfer abstract |
| bklnumber |
58.34 |
| publishDate |
2021 |
| allfields |
10.1016/j.jbiosc.2021.08.009 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001581.pica (DE-627)ELV055854761 (ELSEVIER)S1389-1723(21)00212-7 DE-627 ger DE-627 rakwb eng 610 VZ 540 660 VZ 58.34 bkl Chae, Jayoung verfasserin aut Inhalable nanoparticles delivery targeting alveolar macrophages for the treatment of pulmonary tuberculosis 2021transfer abstract 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Pulmonary tuberculosis is a highly prevalent respiratory disease that affects approximately a quarter of the world's population. The drug treatment protocol for tuberculosis is complex because the Mycobacterium tuberculosis (M. tuberculosis) invades macrophages and begins to infect. Thus treatment usually includes combination therapy with several drugs such as rifampicin, pyrazinamide, isoniazid, and ethambutol over a long dosing period. Therefore, drug-delivery technologies have been developed to improve patient compliance with medication, reduce adverse effects, and increase effectiveness of the treatment. In the present review, we have discussed recent inhalable nanopharmaceutical systems for the treatment of pulmonary tuberculosis and investigated their design and effectiveness. We examined the underlying processes and characteristics of spray-drying technology and studied the formulation of a dry carrier using spray-drying method. Moreover, we reviewed various research articles on pulmonary delivery of nanoparticles using these carriers, and studied their alveolar macrophage targeting ability and therapeutic effects. Further, we appraised the effectiveness of nanoparticle inhalation therapy for the treatment of pulmonary tuberculosis and its potential as a treatment strategy for lung diseases. Pulmonary tuberculosis is a highly prevalent respiratory disease that affects approximately a quarter of the world's population. The drug treatment protocol for tuberculosis is complex because the Mycobacterium tuberculosis (M. tuberculosis) invades macrophages and begins to infect. Thus treatment usually includes combination therapy with several drugs such as rifampicin, pyrazinamide, isoniazid, and ethambutol over a long dosing period. Therefore, drug-delivery technologies have been developed to improve patient compliance with medication, reduce adverse effects, and increase effectiveness of the treatment. In the present review, we have discussed recent inhalable nanopharmaceutical systems for the treatment of pulmonary tuberculosis and investigated their design and effectiveness. We examined the underlying processes and characteristics of spray-drying technology and studied the formulation of a dry carrier using spray-drying method. Moreover, we reviewed various research articles on pulmonary delivery of nanoparticles using these carriers, and studied their alveolar macrophage targeting ability and therapeutic effects. Further, we appraised the effectiveness of nanoparticle inhalation therapy for the treatment of pulmonary tuberculosis and its potential as a treatment strategy for lung diseases. Spray-drying Elsevier Pulmonary tuberculosis Elsevier Alveolar macrophage targeting Elsevier Drug delivery Elsevier Choi, Yonghyun oth Tanaka, Masayoshi oth Choi, Jonghoon oth Enthalten in Elsevier Science Saunders, Richard ELSEVIER Oral Squamous Cell Carcinoma in Three Related Kowari (Dasyuroides byrnei) 2017 Amsterdam [u.a.] (DE-627)ELV020602480 volume:132 year:2021 number:6 pages:543-551 extent:9 https://doi.org/10.1016/j.jbiosc.2021.08.009 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 58.34 Lebensmitteltechnologie VZ AR 132 2021 6 543-551 9 |
| spelling |
10.1016/j.jbiosc.2021.08.009 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001581.pica (DE-627)ELV055854761 (ELSEVIER)S1389-1723(21)00212-7 DE-627 ger DE-627 rakwb eng 610 VZ 540 660 VZ 58.34 bkl Chae, Jayoung verfasserin aut Inhalable nanoparticles delivery targeting alveolar macrophages for the treatment of pulmonary tuberculosis 2021transfer abstract 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Pulmonary tuberculosis is a highly prevalent respiratory disease that affects approximately a quarter of the world's population. The drug treatment protocol for tuberculosis is complex because the Mycobacterium tuberculosis (M. tuberculosis) invades macrophages and begins to infect. Thus treatment usually includes combination therapy with several drugs such as rifampicin, pyrazinamide, isoniazid, and ethambutol over a long dosing period. Therefore, drug-delivery technologies have been developed to improve patient compliance with medication, reduce adverse effects, and increase effectiveness of the treatment. In the present review, we have discussed recent inhalable nanopharmaceutical systems for the treatment of pulmonary tuberculosis and investigated their design and effectiveness. We examined the underlying processes and characteristics of spray-drying technology and studied the formulation of a dry carrier using spray-drying method. Moreover, we reviewed various research articles on pulmonary delivery of nanoparticles using these carriers, and studied their alveolar macrophage targeting ability and therapeutic effects. Further, we appraised the effectiveness of nanoparticle inhalation therapy for the treatment of pulmonary tuberculosis and its potential as a treatment strategy for lung diseases. Pulmonary tuberculosis is a highly prevalent respiratory disease that affects approximately a quarter of the world's population. The drug treatment protocol for tuberculosis is complex because the Mycobacterium tuberculosis (M. tuberculosis) invades macrophages and begins to infect. Thus treatment usually includes combination therapy with several drugs such as rifampicin, pyrazinamide, isoniazid, and ethambutol over a long dosing period. Therefore, drug-delivery technologies have been developed to improve patient compliance with medication, reduce adverse effects, and increase effectiveness of the treatment. In the present review, we have discussed recent inhalable nanopharmaceutical systems for the treatment of pulmonary tuberculosis and investigated their design and effectiveness. We examined the underlying processes and characteristics of spray-drying technology and studied the formulation of a dry carrier using spray-drying method. Moreover, we reviewed various research articles on pulmonary delivery of nanoparticles using these carriers, and studied their alveolar macrophage targeting ability and therapeutic effects. Further, we appraised the effectiveness of nanoparticle inhalation therapy for the treatment of pulmonary tuberculosis and its potential as a treatment strategy for lung diseases. Spray-drying Elsevier Pulmonary tuberculosis Elsevier Alveolar macrophage targeting Elsevier Drug delivery Elsevier Choi, Yonghyun oth Tanaka, Masayoshi oth Choi, Jonghoon oth Enthalten in Elsevier Science Saunders, Richard ELSEVIER Oral Squamous Cell Carcinoma in Three Related Kowari (Dasyuroides byrnei) 2017 Amsterdam [u.a.] (DE-627)ELV020602480 volume:132 year:2021 number:6 pages:543-551 extent:9 https://doi.org/10.1016/j.jbiosc.2021.08.009 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 58.34 Lebensmitteltechnologie VZ AR 132 2021 6 543-551 9 |
| allfields_unstemmed |
10.1016/j.jbiosc.2021.08.009 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001581.pica (DE-627)ELV055854761 (ELSEVIER)S1389-1723(21)00212-7 DE-627 ger DE-627 rakwb eng 610 VZ 540 660 VZ 58.34 bkl Chae, Jayoung verfasserin aut Inhalable nanoparticles delivery targeting alveolar macrophages for the treatment of pulmonary tuberculosis 2021transfer abstract 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Pulmonary tuberculosis is a highly prevalent respiratory disease that affects approximately a quarter of the world's population. The drug treatment protocol for tuberculosis is complex because the Mycobacterium tuberculosis (M. tuberculosis) invades macrophages and begins to infect. Thus treatment usually includes combination therapy with several drugs such as rifampicin, pyrazinamide, isoniazid, and ethambutol over a long dosing period. Therefore, drug-delivery technologies have been developed to improve patient compliance with medication, reduce adverse effects, and increase effectiveness of the treatment. In the present review, we have discussed recent inhalable nanopharmaceutical systems for the treatment of pulmonary tuberculosis and investigated their design and effectiveness. We examined the underlying processes and characteristics of spray-drying technology and studied the formulation of a dry carrier using spray-drying method. Moreover, we reviewed various research articles on pulmonary delivery of nanoparticles using these carriers, and studied their alveolar macrophage targeting ability and therapeutic effects. Further, we appraised the effectiveness of nanoparticle inhalation therapy for the treatment of pulmonary tuberculosis and its potential as a treatment strategy for lung diseases. Pulmonary tuberculosis is a highly prevalent respiratory disease that affects approximately a quarter of the world's population. The drug treatment protocol for tuberculosis is complex because the Mycobacterium tuberculosis (M. tuberculosis) invades macrophages and begins to infect. Thus treatment usually includes combination therapy with several drugs such as rifampicin, pyrazinamide, isoniazid, and ethambutol over a long dosing period. Therefore, drug-delivery technologies have been developed to improve patient compliance with medication, reduce adverse effects, and increase effectiveness of the treatment. In the present review, we have discussed recent inhalable nanopharmaceutical systems for the treatment of pulmonary tuberculosis and investigated their design and effectiveness. We examined the underlying processes and characteristics of spray-drying technology and studied the formulation of a dry carrier using spray-drying method. Moreover, we reviewed various research articles on pulmonary delivery of nanoparticles using these carriers, and studied their alveolar macrophage targeting ability and therapeutic effects. Further, we appraised the effectiveness of nanoparticle inhalation therapy for the treatment of pulmonary tuberculosis and its potential as a treatment strategy for lung diseases. Spray-drying Elsevier Pulmonary tuberculosis Elsevier Alveolar macrophage targeting Elsevier Drug delivery Elsevier Choi, Yonghyun oth Tanaka, Masayoshi oth Choi, Jonghoon oth Enthalten in Elsevier Science Saunders, Richard ELSEVIER Oral Squamous Cell Carcinoma in Three Related Kowari (Dasyuroides byrnei) 2017 Amsterdam [u.a.] (DE-627)ELV020602480 volume:132 year:2021 number:6 pages:543-551 extent:9 https://doi.org/10.1016/j.jbiosc.2021.08.009 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 58.34 Lebensmitteltechnologie VZ AR 132 2021 6 543-551 9 |
| allfieldsGer |
10.1016/j.jbiosc.2021.08.009 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001581.pica (DE-627)ELV055854761 (ELSEVIER)S1389-1723(21)00212-7 DE-627 ger DE-627 rakwb eng 610 VZ 540 660 VZ 58.34 bkl Chae, Jayoung verfasserin aut Inhalable nanoparticles delivery targeting alveolar macrophages for the treatment of pulmonary tuberculosis 2021transfer abstract 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Pulmonary tuberculosis is a highly prevalent respiratory disease that affects approximately a quarter of the world's population. The drug treatment protocol for tuberculosis is complex because the Mycobacterium tuberculosis (M. tuberculosis) invades macrophages and begins to infect. Thus treatment usually includes combination therapy with several drugs such as rifampicin, pyrazinamide, isoniazid, and ethambutol over a long dosing period. Therefore, drug-delivery technologies have been developed to improve patient compliance with medication, reduce adverse effects, and increase effectiveness of the treatment. In the present review, we have discussed recent inhalable nanopharmaceutical systems for the treatment of pulmonary tuberculosis and investigated their design and effectiveness. We examined the underlying processes and characteristics of spray-drying technology and studied the formulation of a dry carrier using spray-drying method. Moreover, we reviewed various research articles on pulmonary delivery of nanoparticles using these carriers, and studied their alveolar macrophage targeting ability and therapeutic effects. Further, we appraised the effectiveness of nanoparticle inhalation therapy for the treatment of pulmonary tuberculosis and its potential as a treatment strategy for lung diseases. Pulmonary tuberculosis is a highly prevalent respiratory disease that affects approximately a quarter of the world's population. The drug treatment protocol for tuberculosis is complex because the Mycobacterium tuberculosis (M. tuberculosis) invades macrophages and begins to infect. Thus treatment usually includes combination therapy with several drugs such as rifampicin, pyrazinamide, isoniazid, and ethambutol over a long dosing period. Therefore, drug-delivery technologies have been developed to improve patient compliance with medication, reduce adverse effects, and increase effectiveness of the treatment. In the present review, we have discussed recent inhalable nanopharmaceutical systems for the treatment of pulmonary tuberculosis and investigated their design and effectiveness. We examined the underlying processes and characteristics of spray-drying technology and studied the formulation of a dry carrier using spray-drying method. Moreover, we reviewed various research articles on pulmonary delivery of nanoparticles using these carriers, and studied their alveolar macrophage targeting ability and therapeutic effects. Further, we appraised the effectiveness of nanoparticle inhalation therapy for the treatment of pulmonary tuberculosis and its potential as a treatment strategy for lung diseases. Spray-drying Elsevier Pulmonary tuberculosis Elsevier Alveolar macrophage targeting Elsevier Drug delivery Elsevier Choi, Yonghyun oth Tanaka, Masayoshi oth Choi, Jonghoon oth Enthalten in Elsevier Science Saunders, Richard ELSEVIER Oral Squamous Cell Carcinoma in Three Related Kowari (Dasyuroides byrnei) 2017 Amsterdam [u.a.] (DE-627)ELV020602480 volume:132 year:2021 number:6 pages:543-551 extent:9 https://doi.org/10.1016/j.jbiosc.2021.08.009 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 58.34 Lebensmitteltechnologie VZ AR 132 2021 6 543-551 9 |
| allfieldsSound |
10.1016/j.jbiosc.2021.08.009 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001581.pica (DE-627)ELV055854761 (ELSEVIER)S1389-1723(21)00212-7 DE-627 ger DE-627 rakwb eng 610 VZ 540 660 VZ 58.34 bkl Chae, Jayoung verfasserin aut Inhalable nanoparticles delivery targeting alveolar macrophages for the treatment of pulmonary tuberculosis 2021transfer abstract 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Pulmonary tuberculosis is a highly prevalent respiratory disease that affects approximately a quarter of the world's population. The drug treatment protocol for tuberculosis is complex because the Mycobacterium tuberculosis (M. tuberculosis) invades macrophages and begins to infect. Thus treatment usually includes combination therapy with several drugs such as rifampicin, pyrazinamide, isoniazid, and ethambutol over a long dosing period. Therefore, drug-delivery technologies have been developed to improve patient compliance with medication, reduce adverse effects, and increase effectiveness of the treatment. In the present review, we have discussed recent inhalable nanopharmaceutical systems for the treatment of pulmonary tuberculosis and investigated their design and effectiveness. We examined the underlying processes and characteristics of spray-drying technology and studied the formulation of a dry carrier using spray-drying method. Moreover, we reviewed various research articles on pulmonary delivery of nanoparticles using these carriers, and studied their alveolar macrophage targeting ability and therapeutic effects. Further, we appraised the effectiveness of nanoparticle inhalation therapy for the treatment of pulmonary tuberculosis and its potential as a treatment strategy for lung diseases. Pulmonary tuberculosis is a highly prevalent respiratory disease that affects approximately a quarter of the world's population. The drug treatment protocol for tuberculosis is complex because the Mycobacterium tuberculosis (M. tuberculosis) invades macrophages and begins to infect. Thus treatment usually includes combination therapy with several drugs such as rifampicin, pyrazinamide, isoniazid, and ethambutol over a long dosing period. Therefore, drug-delivery technologies have been developed to improve patient compliance with medication, reduce adverse effects, and increase effectiveness of the treatment. In the present review, we have discussed recent inhalable nanopharmaceutical systems for the treatment of pulmonary tuberculosis and investigated their design and effectiveness. We examined the underlying processes and characteristics of spray-drying technology and studied the formulation of a dry carrier using spray-drying method. Moreover, we reviewed various research articles on pulmonary delivery of nanoparticles using these carriers, and studied their alveolar macrophage targeting ability and therapeutic effects. Further, we appraised the effectiveness of nanoparticle inhalation therapy for the treatment of pulmonary tuberculosis and its potential as a treatment strategy for lung diseases. Spray-drying Elsevier Pulmonary tuberculosis Elsevier Alveolar macrophage targeting Elsevier Drug delivery Elsevier Choi, Yonghyun oth Tanaka, Masayoshi oth Choi, Jonghoon oth Enthalten in Elsevier Science Saunders, Richard ELSEVIER Oral Squamous Cell Carcinoma in Three Related Kowari (Dasyuroides byrnei) 2017 Amsterdam [u.a.] (DE-627)ELV020602480 volume:132 year:2021 number:6 pages:543-551 extent:9 https://doi.org/10.1016/j.jbiosc.2021.08.009 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 58.34 Lebensmitteltechnologie VZ AR 132 2021 6 543-551 9 |
| language |
English |
| source |
Enthalten in Oral Squamous Cell Carcinoma in Three Related Kowari (Dasyuroides byrnei) Amsterdam [u.a.] volume:132 year:2021 number:6 pages:543-551 extent:9 |
| sourceStr |
Enthalten in Oral Squamous Cell Carcinoma in Three Related Kowari (Dasyuroides byrnei) Amsterdam [u.a.] volume:132 year:2021 number:6 pages:543-551 extent:9 |
| format_phy_str_mv |
Article |
| bklname |
Lebensmitteltechnologie |
| institution |
findex.gbv.de |
| topic_facet |
Spray-drying Pulmonary tuberculosis Alveolar macrophage targeting Drug delivery |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Oral Squamous Cell Carcinoma in Three Related Kowari (Dasyuroides byrnei) |
| authorswithroles_txt_mv |
Chae, Jayoung @@aut@@ Choi, Yonghyun @@oth@@ Tanaka, Masayoshi @@oth@@ Choi, Jonghoon @@oth@@ |
| publishDateDaySort_date |
2021-01-01T00:00:00Z |
| hierarchy_top_id |
ELV020602480 |
| dewey-sort |
3610 |
| id |
ELV055854761 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV055854761</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626042246.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">220105s2021 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.jbiosc.2021.08.009</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001581.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV055854761</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1389-1723(21)00212-7</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="a">660</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">58.34</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Chae, Jayoung</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Inhalable nanoparticles delivery targeting alveolar macrophages for the treatment of pulmonary tuberculosis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">9</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Pulmonary tuberculosis is a highly prevalent respiratory disease that affects approximately a quarter of the world's population. The drug treatment protocol for tuberculosis is complex because the Mycobacterium tuberculosis (M. tuberculosis) invades macrophages and begins to infect. Thus treatment usually includes combination therapy with several drugs such as rifampicin, pyrazinamide, isoniazid, and ethambutol over a long dosing period. Therefore, drug-delivery technologies have been developed to improve patient compliance with medication, reduce adverse effects, and increase effectiveness of the treatment. In the present review, we have discussed recent inhalable nanopharmaceutical systems for the treatment of pulmonary tuberculosis and investigated their design and effectiveness. We examined the underlying processes and characteristics of spray-drying technology and studied the formulation of a dry carrier using spray-drying method. Moreover, we reviewed various research articles on pulmonary delivery of nanoparticles using these carriers, and studied their alveolar macrophage targeting ability and therapeutic effects. Further, we appraised the effectiveness of nanoparticle inhalation therapy for the treatment of pulmonary tuberculosis and its potential as a treatment strategy for lung diseases.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Pulmonary tuberculosis is a highly prevalent respiratory disease that affects approximately a quarter of the world's population. The drug treatment protocol for tuberculosis is complex because the Mycobacterium tuberculosis (M. tuberculosis) invades macrophages and begins to infect. Thus treatment usually includes combination therapy with several drugs such as rifampicin, pyrazinamide, isoniazid, and ethambutol over a long dosing period. Therefore, drug-delivery technologies have been developed to improve patient compliance with medication, reduce adverse effects, and increase effectiveness of the treatment. In the present review, we have discussed recent inhalable nanopharmaceutical systems for the treatment of pulmonary tuberculosis and investigated their design and effectiveness. We examined the underlying processes and characteristics of spray-drying technology and studied the formulation of a dry carrier using spray-drying method. Moreover, we reviewed various research articles on pulmonary delivery of nanoparticles using these carriers, and studied their alveolar macrophage targeting ability and therapeutic effects. Further, we appraised the effectiveness of nanoparticle inhalation therapy for the treatment of pulmonary tuberculosis and its potential as a treatment strategy for lung diseases.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Spray-drying</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Pulmonary tuberculosis</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Alveolar macrophage targeting</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Drug delivery</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Choi, Yonghyun</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tanaka, Masayoshi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Choi, Jonghoon</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Saunders, Richard ELSEVIER</subfield><subfield code="t">Oral Squamous Cell Carcinoma in Three Related Kowari (Dasyuroides byrnei)</subfield><subfield code="d">2017</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV020602480</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:132</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:6</subfield><subfield code="g">pages:543-551</subfield><subfield code="g">extent:9</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.jbiosc.2021.08.009</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">58.34</subfield><subfield code="j">Lebensmitteltechnologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">132</subfield><subfield code="j">2021</subfield><subfield code="e">6</subfield><subfield code="h">543-551</subfield><subfield code="g">9</subfield></datafield></record></collection>
|
| author |
Chae, Jayoung |
| spellingShingle |
Chae, Jayoung ddc 610 ddc 540 bkl 58.34 Elsevier Spray-drying Elsevier Pulmonary tuberculosis Elsevier Alveolar macrophage targeting Elsevier Drug delivery Inhalable nanoparticles delivery targeting alveolar macrophages for the treatment of pulmonary tuberculosis |
| authorStr |
Chae, Jayoung |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV020602480 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health 540 - Chemistry & allied sciences 660 - Chemical engineering |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 VZ 540 660 VZ 58.34 bkl Inhalable nanoparticles delivery targeting alveolar macrophages for the treatment of pulmonary tuberculosis Spray-drying Elsevier Pulmonary tuberculosis Elsevier Alveolar macrophage targeting Elsevier Drug delivery Elsevier |
| topic |
ddc 610 ddc 540 bkl 58.34 Elsevier Spray-drying Elsevier Pulmonary tuberculosis Elsevier Alveolar macrophage targeting Elsevier Drug delivery |
| topic_unstemmed |
ddc 610 ddc 540 bkl 58.34 Elsevier Spray-drying Elsevier Pulmonary tuberculosis Elsevier Alveolar macrophage targeting Elsevier Drug delivery |
| topic_browse |
ddc 610 ddc 540 bkl 58.34 Elsevier Spray-drying Elsevier Pulmonary tuberculosis Elsevier Alveolar macrophage targeting Elsevier Drug delivery |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
y c yc m t mt j c jc |
| hierarchy_parent_title |
Oral Squamous Cell Carcinoma in Three Related Kowari (Dasyuroides byrnei) |
| hierarchy_parent_id |
ELV020602480 |
| dewey-tens |
610 - Medicine & health 540 - Chemistry 660 - Chemical engineering |
| hierarchy_top_title |
Oral Squamous Cell Carcinoma in Three Related Kowari (Dasyuroides byrnei) |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV020602480 |
| title |
Inhalable nanoparticles delivery targeting alveolar macrophages for the treatment of pulmonary tuberculosis |
| ctrlnum |
(DE-627)ELV055854761 (ELSEVIER)S1389-1723(21)00212-7 |
| title_full |
Inhalable nanoparticles delivery targeting alveolar macrophages for the treatment of pulmonary tuberculosis |
| author_sort |
Chae, Jayoung |
| journal |
Oral Squamous Cell Carcinoma in Three Related Kowari (Dasyuroides byrnei) |
| journalStr |
Oral Squamous Cell Carcinoma in Three Related Kowari (Dasyuroides byrnei) |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology 500 - Science |
| recordtype |
marc |
| publishDateSort |
2021 |
| contenttype_str_mv |
zzz |
| container_start_page |
543 |
| author_browse |
Chae, Jayoung |
| container_volume |
132 |
| physical |
9 |
| class |
610 VZ 540 660 VZ 58.34 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Chae, Jayoung |
| doi_str_mv |
10.1016/j.jbiosc.2021.08.009 |
| dewey-full |
610 540 660 |
| title_sort |
inhalable nanoparticles delivery targeting alveolar macrophages for the treatment of pulmonary tuberculosis |
| title_auth |
Inhalable nanoparticles delivery targeting alveolar macrophages for the treatment of pulmonary tuberculosis |
| abstract |
Pulmonary tuberculosis is a highly prevalent respiratory disease that affects approximately a quarter of the world's population. The drug treatment protocol for tuberculosis is complex because the Mycobacterium tuberculosis (M. tuberculosis) invades macrophages and begins to infect. Thus treatment usually includes combination therapy with several drugs such as rifampicin, pyrazinamide, isoniazid, and ethambutol over a long dosing period. Therefore, drug-delivery technologies have been developed to improve patient compliance with medication, reduce adverse effects, and increase effectiveness of the treatment. In the present review, we have discussed recent inhalable nanopharmaceutical systems for the treatment of pulmonary tuberculosis and investigated their design and effectiveness. We examined the underlying processes and characteristics of spray-drying technology and studied the formulation of a dry carrier using spray-drying method. Moreover, we reviewed various research articles on pulmonary delivery of nanoparticles using these carriers, and studied their alveolar macrophage targeting ability and therapeutic effects. Further, we appraised the effectiveness of nanoparticle inhalation therapy for the treatment of pulmonary tuberculosis and its potential as a treatment strategy for lung diseases. |
| abstractGer |
Pulmonary tuberculosis is a highly prevalent respiratory disease that affects approximately a quarter of the world's population. The drug treatment protocol for tuberculosis is complex because the Mycobacterium tuberculosis (M. tuberculosis) invades macrophages and begins to infect. Thus treatment usually includes combination therapy with several drugs such as rifampicin, pyrazinamide, isoniazid, and ethambutol over a long dosing period. Therefore, drug-delivery technologies have been developed to improve patient compliance with medication, reduce adverse effects, and increase effectiveness of the treatment. In the present review, we have discussed recent inhalable nanopharmaceutical systems for the treatment of pulmonary tuberculosis and investigated their design and effectiveness. We examined the underlying processes and characteristics of spray-drying technology and studied the formulation of a dry carrier using spray-drying method. Moreover, we reviewed various research articles on pulmonary delivery of nanoparticles using these carriers, and studied their alveolar macrophage targeting ability and therapeutic effects. Further, we appraised the effectiveness of nanoparticle inhalation therapy for the treatment of pulmonary tuberculosis and its potential as a treatment strategy for lung diseases. |
| abstract_unstemmed |
Pulmonary tuberculosis is a highly prevalent respiratory disease that affects approximately a quarter of the world's population. The drug treatment protocol for tuberculosis is complex because the Mycobacterium tuberculosis (M. tuberculosis) invades macrophages and begins to infect. Thus treatment usually includes combination therapy with several drugs such as rifampicin, pyrazinamide, isoniazid, and ethambutol over a long dosing period. Therefore, drug-delivery technologies have been developed to improve patient compliance with medication, reduce adverse effects, and increase effectiveness of the treatment. In the present review, we have discussed recent inhalable nanopharmaceutical systems for the treatment of pulmonary tuberculosis and investigated their design and effectiveness. We examined the underlying processes and characteristics of spray-drying technology and studied the formulation of a dry carrier using spray-drying method. Moreover, we reviewed various research articles on pulmonary delivery of nanoparticles using these carriers, and studied their alveolar macrophage targeting ability and therapeutic effects. Further, we appraised the effectiveness of nanoparticle inhalation therapy for the treatment of pulmonary tuberculosis and its potential as a treatment strategy for lung diseases. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA |
| container_issue |
6 |
| title_short |
Inhalable nanoparticles delivery targeting alveolar macrophages for the treatment of pulmonary tuberculosis |
| url |
https://doi.org/10.1016/j.jbiosc.2021.08.009 |
| remote_bool |
true |
| author2 |
Choi, Yonghyun Tanaka, Masayoshi Choi, Jonghoon |
| author2Str |
Choi, Yonghyun Tanaka, Masayoshi Choi, Jonghoon |
| ppnlink |
ELV020602480 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth |
| doi_str |
10.1016/j.jbiosc.2021.08.009 |
| up_date |
2024-07-06T18:43:39.483Z |
| _version_ |
1803856295477903360 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV055854761</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626042246.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">220105s2021 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.jbiosc.2021.08.009</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001581.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV055854761</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1389-1723(21)00212-7</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="a">660</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">58.34</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Chae, Jayoung</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Inhalable nanoparticles delivery targeting alveolar macrophages for the treatment of pulmonary tuberculosis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">9</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Pulmonary tuberculosis is a highly prevalent respiratory disease that affects approximately a quarter of the world's population. The drug treatment protocol for tuberculosis is complex because the Mycobacterium tuberculosis (M. tuberculosis) invades macrophages and begins to infect. Thus treatment usually includes combination therapy with several drugs such as rifampicin, pyrazinamide, isoniazid, and ethambutol over a long dosing period. Therefore, drug-delivery technologies have been developed to improve patient compliance with medication, reduce adverse effects, and increase effectiveness of the treatment. In the present review, we have discussed recent inhalable nanopharmaceutical systems for the treatment of pulmonary tuberculosis and investigated their design and effectiveness. We examined the underlying processes and characteristics of spray-drying technology and studied the formulation of a dry carrier using spray-drying method. Moreover, we reviewed various research articles on pulmonary delivery of nanoparticles using these carriers, and studied their alveolar macrophage targeting ability and therapeutic effects. Further, we appraised the effectiveness of nanoparticle inhalation therapy for the treatment of pulmonary tuberculosis and its potential as a treatment strategy for lung diseases.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Pulmonary tuberculosis is a highly prevalent respiratory disease that affects approximately a quarter of the world's population. The drug treatment protocol for tuberculosis is complex because the Mycobacterium tuberculosis (M. tuberculosis) invades macrophages and begins to infect. Thus treatment usually includes combination therapy with several drugs such as rifampicin, pyrazinamide, isoniazid, and ethambutol over a long dosing period. Therefore, drug-delivery technologies have been developed to improve patient compliance with medication, reduce adverse effects, and increase effectiveness of the treatment. In the present review, we have discussed recent inhalable nanopharmaceutical systems for the treatment of pulmonary tuberculosis and investigated their design and effectiveness. We examined the underlying processes and characteristics of spray-drying technology and studied the formulation of a dry carrier using spray-drying method. Moreover, we reviewed various research articles on pulmonary delivery of nanoparticles using these carriers, and studied their alveolar macrophage targeting ability and therapeutic effects. Further, we appraised the effectiveness of nanoparticle inhalation therapy for the treatment of pulmonary tuberculosis and its potential as a treatment strategy for lung diseases.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Spray-drying</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Pulmonary tuberculosis</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Alveolar macrophage targeting</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Drug delivery</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Choi, Yonghyun</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tanaka, Masayoshi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Choi, Jonghoon</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Saunders, Richard ELSEVIER</subfield><subfield code="t">Oral Squamous Cell Carcinoma in Three Related Kowari (Dasyuroides byrnei)</subfield><subfield code="d">2017</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV020602480</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:132</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:6</subfield><subfield code="g">pages:543-551</subfield><subfield code="g">extent:9</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.jbiosc.2021.08.009</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">58.34</subfield><subfield code="j">Lebensmitteltechnologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">132</subfield><subfield code="j">2021</subfield><subfield code="e">6</subfield><subfield code="h">543-551</subfield><subfield code="g">9</subfield></datafield></record></collection>
|
| score |
7.4006386 |